FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
8.15
+0.03 (0.37%)
Dec 4, 2025, 4:00 PM EST - Market closed
FibroGen Revenue
FibroGen had revenue of $1.08M in the quarter ending September 30, 2025, with 774.80% growth. This brings the company's revenue in the last twelve months to $8.30M. In the year 2024, FibroGen had annual revenue of $29.62M, down -36.71%.
Revenue (ttm)
$8.30M
Revenue Growth
-36.71%
P/S Ratio
4.02
Revenue / Employee
$36,880
Employees
225
Market Cap
32.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
| Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FGEN News
- 24 days ago - FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - FibroGen to Report Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 3 months ago - FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - GlobeNewsWire
- 4 months ago - FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - FibroGen to Report Second Quarter 2025 Financial Results - GlobeNewsWire